NEW YORK — The National Advertising Division last week recommended that Interhealth Nutraceuticals discontinue certain claims for the company’s Zychrome dietary supplements, products that are promoted for the management of insulin levels.
Print and internet claims made by Interhealth for its Zychrome chromium compound, also known as chromium dinicocysteinate, were challenged by Nutrition 21, the manufacturer of a competing product, Chromax, a chromium picolinate product. Interhealth had been making comparison claims against the supplement ingredient in Chromax.
Following its review of the evidence in the record, NAD recommended that the advertiser discontinue all claims at issue, with one exception: CDNC is a new form of chromium compound, a fact that the advertiser is free to promote. However, NAD recommended that the advertiser modify its “next generation” claims to avoid conveying the message that Zychrome is superior to chromium picolinate.
InterHealth Nutraceuticals, in its advertiser’s statement, reported the company “will modify advertising for Zychrome in accordance with the NAD’s recommendations.”
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.